Cardiol Therapeutics (CRDL) Change in Cash (2020 - 2026)

Cardiol Therapeutics (CRDL) has 7 years of Change in Cash data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Change in Cash rose 187.95% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 172.93% YoY) and the FY2025 annual result came in at -$6.0 million, down 33.83% from the prior year.
• Change in Cash eased to $4.4 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $9.4 million in Q4 2024 to a low of -$9.3 million in Q4 2022.
• A 5-year average of -$2.7 million and a median of -$4.0 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash plunged 362.27% — and 2024, when it soared 296.6%.
• Tracing CRDL's Change in Cash over 5 years: stood at -$9.3 million in 2022, then soared by 48.68% to -$4.8 million in 2023, then soared by 296.6% to $9.4 million in 2024, then fell by 21.04% to $7.4 million in 2025, then sank by 40.53% to $4.4 million in 2026.
• The last three Change in Cash figures came in at $4.4 million (Q1 2026), $7.4 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.